➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Baxter
Johnson and Johnson
Express Scripts
AstraZeneca

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Patent: 9,782,406

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,782,406
Title:Kinase inhibitor and method for treatment of related diseases
Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.
Inventor(s): Pan; Zhengying (Shenzhen, CN), Li; Xitao (Shenzhen, CN)
Assignee: Peking University Shenzhen Graduate School (Shenzhen, CN) Beijing Reciprocapharmaceuticals Co., Ltd. (Beijing, CN)
Application Number:14/830,128
Patent Claims:see list of patent claims

Details for Patent 9,782,406

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Peking University Shenzhen Graduate School (Shenzhen, CN) Beijing Reciprocapharmaceuticals Co., Ltd. (Beijing, CN) 2031-10-25 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Peking University Shenzhen Graduate School (Shenzhen, CN) Beijing Reciprocapharmaceuticals Co., Ltd. (Beijing, CN) 2031-10-25 RX Orphan search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23   Start Trial Peking University Shenzhen Graduate School (Shenzhen, CN) Beijing Reciprocapharmaceuticals Co., Ltd. (Beijing, CN) 2031-10-25 RX Orphan search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04   Start Trial Peking University Shenzhen Graduate School (Shenzhen, CN) Beijing Reciprocapharmaceuticals Co., Ltd. (Beijing, CN) 2031-10-25 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04   Start Trial Peking University Shenzhen Graduate School (Shenzhen, CN) Beijing Reciprocapharmaceuticals Co., Ltd. (Beijing, CN) 2031-10-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Boehringer Ingelheim
Moodys
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.